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Antibodies against N-methyl-D-aspartate receptor
(NMDAR) are identified in the form of immune-
mediated encephalitis in which typical manifesta-
tions include neuropsychiatric symptoms, seizures,
abnormal movements, dysautonomia and hypoven-
tilation. The authors report two cases of anti-NMDAR
encephalitis with different presentations and patterns
of progression. The first patient presented with status
epilepticus and later developed psychosis, pyramidal
signs and diffuse encephalopathy. The second patient
presented with acute psychosis followed a week later
by seizures, dystonia, rigidity, oromandibular dyski-
nesias and dysautonomia. Possible mechanisms
responsible for the clinical manifestations of this
disease are discussed in light of recently described
additional clinical and laboratory findings.
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ENCEPHALITIS WITH ANTIBODIES againstN-methyl-D-aspartate receptors (anti-NMDAR) is
an immune-mediated encephalitis in which antibod-
ies against neuronal surface antigens are found.1 In
2005, patients with paraneoplastic encephalitis pre-
senting with psychiatric manifestations, short-term
memory loss, hypoventilation and autoantibodies
against unknown neuropil antigens were described.2,3
Subsequently, antibodies against NMDAR-NR1/NR2
heteromers were identified, and NR1 was considered
the crucial epitope.4,5 Patients were young adult
women with typical manifestations: initial psychiat-
ric symptoms followed by seizures, dyskinesias,
chorea, autonomic instability and central hypo-
ventilation. Psychiatric manifestations are variable,
including anxiety, bizarre behavior, mania, halluci-
nations, delusions, and pose diagnostic difficulties at
onset. Lymphocytic pleocytosis, high protein or posi-
tive oligoclonal bands in cerebrospinal fluid (CSF)
are frequent.5 Pattern of progression and spectrum of
manifestations led to the hypothesis of immunologi-
cal response spreading against other central nervous
system antigens.6,7 We report two patients with anti-
NMDAR encephalitis and discuss underlying patho-
physiologic mechanisms.
CASE REPORTS
Case 1
A 63-year-old Caucasian male with a medical history
of febrile seizures was admitted for left facial motor
status epilepticus. Despite treatment with phenytoin
and valproate, he developed convulsive status epilep-
ticus, requiring intensive care unit admission. CSF
revealed high protein (0.78 g/L), positive unmatched
oligoclonal bands, but was otherwise normal, includ-
ing herpes simplex virus polymerase chain reaction
(HSV-PCR). IV acyclovir was administered for
14 days. Brain magnetic resonance imaging (day 1)
showed multiple cortical lesions (Fig. 1). On day 4,
he had decreased consciousness, severe dysarthria
and dysphagia, left hemiparesis and electroencepha-
lography (EEG) showed a right temporal status
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epilepticus. Subsequently he developed persecutory
delusions, and visual and auditory hallucinations
which improved with olanzapine. During psychosis,
EEG revealed moderate encephalopathy and no
epileptiform activity. Extensive blood testing was
normal. Between days 20 and 58 he became progres-
sively stuporous with bilateral extensor plantars.
High-dose IV methylprednisolone, followed by a
5-day course of IV immunoglobulins (IgIV), led to
significant clinical improvement. Investigation for
occult tumor was negative. Recurrence of psychosis
occurred 1 month later, and examination revealed
dysarthria, multifocal myoclonus and ataxic gait.
Phenytoin intoxication was found, it was replaced
by levetiracetam and after a 5-day course of IgIV,
he recovered rapidly and has been asymptomatic
for 3 years. Anti-NMDAR NR2B analysis was per-
formed using a Western blot technique:8 antibodies
in serum were IgG-positive and IgM-negative; in
CSF both IgG and IgM were negative (samples
collected several weeks after presentation and IV
methylprednisolone).
Case 2
A 21-year-old previously healthy Caucasian woman
was admitted for acute onset of delusions, ideas of
grandeur, and visual and auditory hallucinations.
Recent hallucinogenic drug ingestion was suspected.
She had received a booster vaccination against
tetanus 3 days earlier and since then had flu-like
symptoms. She was admitted to the Psychiatry
Department, treated with risperidone, diazepam and
a week later had a generalized seizure. At first neuro-
logical evaluation she was drowsy, with no verbal
response, had generalized right-side predominant
rigidity, with catatonia cerea, dystonia of the upper
limbs, oromandibular dyskinesias and episodes of
sinus tachycardia and peripheral desaturation. Exten-
sive blood testing and urine toxicological screen were
normal. CSF showed lymphocytic pleocytosis (10
cells/uL, 95% lymphocytes) and was otherwise
normal including HSV-PCR and oligoclonal bands.
Brain magnetic resonance imaging was normal
(including T2, diffusion-weighted imaging and
contrast-T1). EEG revealed left frontotemporal
status epilepticus. Status epilepticus persisted despite
phenytoin, levetiracetam and clonazepam. Brain
positron emission tomography (PET) scan revealed
left frontotemporal and left basal ganglia hyperme-
tabolism (Fig. 2). Treatment with IgIV during 5 days
and, later, a 5-day course of IV methylprednisolone
led to progressive clinical improvement. At discharge
she had attention and arithmetic deficits, global dys-
phasia and normal motor exam. She scored 17 in a
Mini Mental State Examination. Investigation for
occult tumor was negative, slow cognitive and lan-
guage improvement was documented as the patient
gradually recovered functional independence, with
more than 18 months of follow up. Immunofluores-
cent cell-based assay was used to determine anti-
NMDAR NR1/NR2:6 serum and CSF collected
3 weeks after admission were positive for anti-
NMDAR NR1/NR2.
Figure 1. Brain magnetic resonance
imaging, fluid attenuated inversion
recovery – hyperintense lesions in
right fronto-opercular, (a) right
insular and (b) bilateral temporal
cortex. Absent diffusion-weighted
imaging abnormality or contrast
enhancement.
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DISCUSSION
Early clinical manifestations in both patients (convul-
sive status epilepticus and psychiatric manifestations)
were likely secondary to cortical dysfunction. Sug-
gested underlying mechanisms include direct
neuronal damage of anti-NMDAR antibodies, cell
deposition of membrane attack complex, antibody-
mediated NMDAR internalization and decreased
synaptic NMDAR-mediated postsynaptic currents.9
Additional manifestations developed in a time-
dependent pattern: acute psychosis and other deficits
in the first patient were possibly secondary to wide-
spread cortical dysfunction, while the second patient
developed basal ganglia and brainstem signs. Findings
must be interpreted with caution. Antibodies against
NMDAR-NR2B determined by Takahashi and col-
laborators’ technique were found in a heterogeneous
population of patients.10–12 NMDAR are transmem-
brane proteins consisting of a combination of NR1,
NR2 (A-D) and NR3 (A-B) subunits.13 Since NR2B
subunits have neocortical and hippocampal expres-
sion, this may explain the early cortical dysfunction of
anti-NMDAR encephalitis. Widespread expression
of NR1 subunits (neurons, oligodendrocytes, astro-
cytes14,15) could explain the spectrum of manifesta-
tions, but fails to explain the temporal pattern
previously described. Myelin basic protein autoanti-
bodies were identified in a patient with anti-NMDAR
encephalitis who later developed transverse myelitis,
optic neuritis and white matter lesions.7 Evidence of
unmatched CSF oligoclonal bands in a later stage of
anti-NMDAR encephalitis suggests the possibility
of spreading of immunological response to other
epitopes, leading to extra-cortical manifestations.6 An
important limitation of the current report consists of
the low specificity of anti-NMDAR-NR2B technique
developed by Takahashi and collaborators, and paired
analysis of serum and CSF from the same patients
using both techniques could further clarify this point.
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